Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of “Moderate Buy” from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received an average recommendation of “Moderate Buy” from the twenty-three analysts that are presently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $367.20.

ALNY has been the subject of a number of recent analyst reports. BMO Capital Markets reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. TD Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Citigroup reduced their price target on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Truist Financial dropped their price objective on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Finally, Raymond James Financial upgraded shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target on the stock in a report on Monday, August 3rd.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $255.96 on Tuesday. The company’s 50-day moving average price is $244.26 and its 200-day moving average price is $283.36. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a twelve month low of $197.81 and a twelve month high of $495.55. The company has a market cap of $34.25 billion, a PE ratio of 47.58 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the business posted ($0.51) earnings per share. The company’s quarterly revenue was up 66.9% compared to the same quarter last year. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post 6.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Norges Bank purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $895,816,000. Legal & General Group Plc purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth $278,321,000. Bank of New York Mellon Corp purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth $148,128,000. Canada Pension Plan Investment Board bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $100,618,000. Finally, Korea Investment CORP bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $74,553,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).